Interactions between Platelets and Human Hepatoma Cell Lines: The Influence of Endothelial Cells

References

• Karpatkin S, Pearlslein E. Role of platelets in tumour cell metastasis. Ann Intern Med 1981; 95: 646–641
   Google Scholar
• Gasic G J, Gasic T B, Stewart C C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46–52
   PubMed Web of Science ®Google Scholar
• Hilgard P, Gordon-Smith E C. Microangiopathic haemolytic anaemia and experimental tumour cell emboli. Br J Haematol 1974; 26: 651–659
   PubMed Web of Science ®Google Scholar
• Sdela W F, Tralka T S, Ketcham A S. Electron microscopic observations on formation of pulmonary melastases. J Surg Res 1975; 18: 137–161
   Google Scholar
• Gasic G J, Gasic T B, Galanti N, Johnson T, Murphy S. Platelet-tumour cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704–708
   PubMed Web of Science ®Google Scholar
• Pearlstein E, Cooper L B, Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1979; 93: 332–344
   PubMedGoogle Scholar
• Pearlstein E, Smerling A, Karpatkin S. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblasts. J Lab Clin Med 1980; 96: 994–1001
   Google Scholar
• Hata Y, Steiner M, Baldini M G. Characterization of the platelet-aggregating activity of tumour cells. Cancer Res 1980; 40: 1217–1222
   Google Scholar
• Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of the platelet aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumour with a specific thrombin inhibitor: dansylarginine an anaplastic murine tumour with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-l, 5-pentanediyl)amide. Cancer Res 1981; 41: 4535–4539
   Google Scholar
• Bastida E, Ordinas A, Giardina L, Jamieson G A. Differentiation of platelet-aggregating effects of human tumour cell lines based on inhibition studies with apyrase. rudin and phospholipase. Cancer Res 1982; 42: 4348–4352
   PubMed Web of Science ®Google Scholar
• Lerner W A, Pearlstein E, Ambrogio C, Karpatkin S A. new mechanism for tumour-induced platelet aggregation. Comparison with mechanisms shared by other tumours with possible pharmacological strategy toward preventing of metastases. Int J Cancer 1983; 31: 463–469
   PubMed Web of Science ®Google Scholar
• Menter D G, Onoda J M, Moilanen D, Sloane B F, Taylor J, Dmonn K V. Inhibition by prostacyclin of the tumour cell induced platelet release reaction and platelet aggregation. J Natl Cancer Inst 1987; 78: 961–969
   Google Scholar
• Honn K V, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 1981; 212: 1270–1272
   PubMed Web of Science ®Google Scholar
• Karpatkin S, Ambrogio C, Pearlstein E. Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res 1984; 44: 3880–3883
   Google Scholar
• Moncada S, Radomski M W, Palmer R M. J Endothelial cell relaxing factor. Biochem Pharmacol 1988; 37: 2495–2501
   PubMed Web of Science ®Google Scholar
• Skinner V O, Bruckdorfer K R. Platelet aggregation induced by hepatocellular carcinoma cell line. Biochem Soc Trans 1987; 15: 516–517
   Google Scholar
• Skinner V O, Bruckdorfer K R. Interactions between HepG2 human hepatoma cells, platelets and endothelial cells. Biochem Soc Trans 1987; 17: 508–509
   Google Scholar
• Dunn R C, Schachter M, Miles C M M, et al. Low-density lipoproteins increase intracellular calcium in aequorin-loaded platelets. FEBS Lett 1988; 238: 357–360
   PubMed Web of Science ®Google Scholar
• Hassall D G, Owen J S, Bruckdorfer K R. The aggregation of isolated platelets in the presence of lipoproteins and prostacyclin. Biochem J 1983; 216: 43–49
   PubMed Web of Science ®Google Scholar
• Gordon J L, Martin W. Stimulation of endothelial prostacyclin production plays no role in endothelium-dependent relaxation of pig aorta. Br J Pharmacol 1983; 80: 179–186
   Google Scholar
• Palmer R M J, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing activity. Nature (Lond.) 1987; 327: 524–526
   PubMed Web of Science ®Google Scholar
• Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Cohn E J, Strong E J, Hughes, et al. Preparation and properties of serum and plasma proteins IV. J Am Chem Soc 1946; 72: 454–475
   Google Scholar
• Haas T A, Bastida E, Nakamura K, Hullin F, Admirall L, Buchanan M R. Binding of 13-HODE and 15ĤTE to endothelial cells and subsequent platelet, neutrophil and tumour cell adhesion. Biochim Biophys Acta 1988; 961: 153–159
   PubMedGoogle Scholar
• Gryglewski R J, Moncada S, Palmer R M J. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 1986; 87: 685–694
   PubMed Web of Science ®Google Scholar
• Alheid U, Reichwehr Forstermann U. Human endothelial cells inhibit platelet aggregation by separate stimulating platelet cyclic AMP and cyclic GMP. Eur J Pharmacol 1989; 164: 103–110
   Google Scholar
• Estrada J, Nicholson G L. Tumour cell platelet aggregating activity does not correlate with metastatic potential of rat 13762NF mammary adenocarcinoma tumor cell clones. Int J Cancer 1984; 34: 101–105
   Google Scholar
• Grignani G, Pacchiarini L, Almasio P. Characterisation of the platelet-aggregating activity of cells with different metastatic potential. Int J Cancer 1986; 38: 237–244
   Google Scholar